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Abstract 
Investigation of vascularity and hypoxia in tumors is important in understanding cancer biology to develop the 
therapeutic strategies in cancer treatment. Recently, an imaging technology with the VECT or SPECT/PET/CT 
small-animal scanner (MILabs) has been developed to obtain simultaneous images using two different tracers 
labeled with SPECT and PET nuclides, respectively. In this study, we developed a method to simultaneously 
visualize vascularity and hypoxia with a human colon carcinoma HT-29tumor-bearing mouse model with 99mTc-
labeled human serum albumin (99mTc-HSA) to detect blood pool, and 64Cu-diacetyl-bis (N4-
methylthiosemicarbazone) (64Cu-ATSM) to detect the over-reduced conditions under hypoxia, by applying this 
SPECT/PET/CT technology. Prior to the in vivo experiments, a phantom study was conducted to confirm 
quantitativity  of the 99mTc/64Cu dual-isotope imaging with the SPECT/PET/CT system, by comparing radio 
activities detected by SPECT/PET/CT system and those of standards under the conditions of wide range of radio 
activities and various content ratios, in our settings. An in vivo imaging study was conducted with HT-29 tumor-
bearing mice. Both 64Cu-ATSM (37 MBq) and 99mTc-HSA (18.5 MBq) were intravenously injected into a 
mouse (n = 4) at 1 h and 10 min, respectively, before scanning for 20 min; the 99mTc/64Cu dual-isotope 
SPECT/PET/CT images were then obtained. The phantom study demonstrated that this system has high 
quantitativity, even when 2 isotopes co-existed and the content ratio was changed over a wide range, indicating 
the feasibility for in vivo experiments. In vivo SPECT/PET/CT imaging with 64Cu-ATSM and 99mTc-HSA 
visualized the distribution of each probe and showed that 64Cu-ATSM high-uptake regions barely overlapped 
with 99mTc-HSA high-uptake regions within HT-29 tumors. We developed a method to simultaneously visualize 
vascularity and hypoxia within HT-29tumors using in vivodual-isotope SPECT/PET/CT imaging. This 
methodology would be useful for studies on cancer biology with mouse tumor models and development of the 
treatment strategies against cancer. 
Examination of vascularity and hypoxia within in vivotumors is important in understanding the biology of cancer 
and development of the therapeutic strategies in cancer treatment. For hypervascular tumors, antiangiogenic 
therapy and antivascular therapy are promising approaches. For antiangiogenic therapy, the anti-vascular 
endothelial growth factor antibody bevacizumab is now clinically used worldwide [1-4], and for antivascular 
therapy, a clinical trial with combrestatin A4 phosphate is conducted [5]. For hypovascular tumor, which is 
usually associated with hypoxia, intensive treatment is necessary, since tumor hypoxia is reportedly resistant to 
chemotherapy and radiotherapy [6-8]. In recent years, several therapeutic methods have been proposedto damage 
to hypoxic regions within tumors, such as intensity modulated radiation therapy with hypoxia positron emission 
tomography (PET) imaging [9, 10], and carbon-ion radiotherapy, which is able to damage tumor cells even in the 
absence of oxygen by high linear energy transfer beam [11, 12]. However, considering the difficulty of cancer 
radical cure at the present moment, more effective drugs and treatment methods for antiangiogenic, antivascular, 
and antihypoxia therapies need to be developed. In addition, combinations of these therapies would be effective 
approaches, since they can attack tumor vascularity and hypoxia closely linked each other. However, it is still 
difficult to observe tumor vascularity and hypoxia both coincidently and concisely in in vivo tumor-bearing 
mouse model. 
Recently, a technology of single-photon emission computed tomography/positron emission 
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tomography/computed tomography (SPECT/PET/CT) imaging with the VECT or small-animal scanner, launched 
from MILabs (Utrecht, Netherlands), has been reported to obtain truly simultaneous images with two tracers 
labeled with SPECT and PET nuclides, respectively. Conventionally, dual-isotope imaging studies with SPECT 
and PET have been performed by obtaining each image independently with 2 separate systems [13, 14]. In 
contrast, the VECT or system is equipped with a clustered pinhole collimator, which dramatically reduces 
pinhole-edge penetration of high-energy annihilation γ-photons from PET nuclides and enables it to detect high-
energy γ-photons derived from PET nuclides, in a manner similar to SPECT nuclides, and to obtain high-
resolution images from positron emitters and single-photon emitters at the same time by separating the images 
based on the photon energy [15, 16]. Thus, this system has a novel concept to make images of PET nuclides, 
compared to the typical PET system, which measures the coincidence of annihilation γ-photons. Goorden et al. 
have reported that this system shows high spatial resolution, with 0.8 mm for PET nuclides and 0.5 mm for 
SPECT nuclides [15]. Miwa et al. also confirmed its performance in simultaneous detection of 99mTc and 18F 
using this system [17].  
In this study, we developed a methodology to easily observe in tratumoral vascularity and hypoxia in a 
simultaneous manner, by applying this SPECT/PET/CT technology. We used 99mTc-labeled human serum 
albumin (99mTc-HSA) labeled with a SPECT nuclide 99mTc (half-life = 6.0 h; 140 keV γ-ray: 89%) to visualize 
tumor vascularity by detecting blood pool [18]. The 99mTc-HSAhas been reported to detect tumor blood pool in 
many types of cancer, including colon cancer, renal cell carcinoma, and liver tumor in both preclinical and 
clinical studies [19-21]. We also used 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), labeled 
with a PET nuclide 64Cu (half-life = 12.7 h; β+-decay: 17.4%; β−-decay: 38.5%; and electron capture: 43%) [22], 
to detect tumor hypoxia. The Cu-ATSM, labeled with Cu radioisotopes, such as 60Cu, 62Cu, and 64Cu, has been 
developed as an imaging agent targeting hypoxic regions in tumors for use with PET [23-26].Many studies have 
demonstrated that Cu-ATSM accumulation is associated with hypoxic conditions of tumor in vitro and in 
vivo[26-29]. The mechanism of radiolabeled Cu-ATSM accumulation has been studied: Cu-ATSM has small 
molecular size and high membrane permeability, and thus rapidly diffuses into cells and is reduced and trapped 
within cells under highly reduced intracellular conditions such as hypoxia [24, 29-31]. A clinical study with 62Cu-
ATSM demonstrated that high levels of hypoxia-inducible factor-1α (HIF-1α) expression were found in Cu-
ATSM uptake regions in the tumors of patients with glioma [32]. In this study, we performed simultaneous in 
vivo imaging using a SPECT/PET/CT with 99mTc-HSA and 64Cu-ATSM for detecting tumor vascularity and 
hypoxia with a HT-29 tumor-bearing mouse model. 
Keywords: 64Cu-ATSM; hypoxia; dual-isotope imaging; PET;SPECT; 99mTc-HSA; vascularity. 
1. Materials and Methods 
1.1. Preparation of radiochemical compounds 
In this study, we used 99mTc as a SPECT nuclide and 64Cu as a PET nuclide. The 99mTc-pertechnetate was 
purchased from Nihon Medi-Physics (Tokyo, Japan). The 64Cu was produced in the cyclotron facility in our 
institution, as reported previously [33] and dissolved in 0.1 M ammonium citrate (pH: 5.5). For the phantom 
study, the 99mTc and the 64Cu solutions were used. For the in vivo study, a blood pool-detecting agent (99mTc-
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HSA) and a hypoxia-detecting agent (64Cu-ATSM) were synthesized. For the 99mTc-HSA, we used the Techne 
Albumin Kit (Fujifilm RI Pharma, Tokyo, Japan), according to the manufacturer’s protocol. The synthesis of 
64Cu-ATSM was performed as previously described [34]. 
1.2. SPECT/PET/CT imaging 
The VECT or small-animal scanner (MILabs, Utrecht, Netherlands) with the tungsten collimator and the NaI(Tl) 
crystal detectors, was used for SPECT/PET/CT imaging. The mouse PET 0.7 collimator, which contains 48 
clusters of four 0.7-mm diameter pinholes placed in 4 rings, and whose central field of view is approximately 12 
mm in diameter and approximately 9 mm in longitudinal length [15], was used in this study. Simultaneous 
SPECT/PET/CT scan was performed for 20 min by list-mode acquisitions using the manufacturer’s software 
(version 3.6g3s, MILabs). For CT, non-contrast-enhanced acquisitions were performed with the following 
parameters: 60 kV tube voltage, 615 μAtube current, partial scan angle, and fast scan mode. The SPECT/PET 
projections were reconstructed with a pixel-based, ordered-subsets expectation maximization algorithm [35] by a 
software attached to the VECT or (version 2.38c), and the triple-energy window method [36] was used for scatter 
correction with the following parameters: for 99mTc, photo peak windows was set to a width of 29%; background 
= 10% on left side and 7% on right side of the photo peak; 16 subset; 15 iteration; 0.4-mm voxel size; and no 
filter, and for 64Cu, photo peak window was set to a width of 30.2%; background = 10% on left side and 7% on 
right side of the photo peak; 32 subset; 15 iteration; 0.4-mm voxel size; and no filter. These parameters were 
decided based on [15, 37]. Registration of the reconstructed SPECT, PET, and CT images was performed with 
the software (version 2.38c). Registered SPECT/PET/CT images were analyzed by the biomedical image 
quantification software PMOD (PMOD Technologies Ltd, Zürich, Switzerland). Radioactivity density values 
(kBq/cc) on SPECT and PET images were determined based on the calibration with a known activity 
concentration using the decay correction.  
1.3. Phantom study 
To confirm quantitativity  of the 99mTc/64Cu dual-isotope imaging using the VECT or SPECT/PET/CT system in 
our settings, a phantom study was performed under the conditions of wide range of radio activities and various 
content ratios. For the phantom study, cylindrical phantoms made of 1-ml syringes (Terumo, Tokyo, Japan) 
containing 100 μl radioactive solutions were used. In phantom study 1, we performed a comparison of 
quantitativity  between phantoms containing mixed dual isotopes (99mTc + 64Cu) and each single isotope (99mTc or 
64Cu). For this experiment, we prepared phantoms containing mixed dual isotopes in various concentrations with 
a radioactivity ratio 99mTc :64Cu = 1 : 2 and each single isotope (99mTc or 64Cu), as shown in Table 1. 
In phantom study 2, quantitativity  was examined with dual isotope (99mTc + 64Cu) samples mixed at different 
ratios. For this experiment, 99mTc was mixed with a given amount of 64Cu at various ratios in the phantoms, as 
seen in Table 2. Radioactivity determined with a dose calibrator (IGC-7 curiemeter; Hitachi Aloka Medical, 
Tokyo, Japan) was enclosed in the phantoms; this radioactivity was used as a reference standard in phantom 
studies 1 and 2. From the obtained SPECT and PET images, the radioactivity of the phantoms was calculated 
with the radioactivity density values, which were determined as described above. 
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1.4. In vivo99mTc/64Cu dual-isotope imaging with HT-29 tumor-bearing mouse model 
Mice bearing human colon carcinoma HT-29 tumors were used in this study. The HT-29 cells (HTB-38; 
American Type Culture Collection, Manassas, VA) were incubated in a humidified atmosphere of 5% CO2 in air 
at 37°C. We used Dulbecco’s modified Eagle’s medium, supplemented with 10% fetal bovine serum and 
antibiotics as the growth medium. Exponentially growing cells were used in this study. 
Table 1: Radioactivity concentration in the phantoms used in phantom study 1 
Single-isotope phantoms  
99mTc alone (kBq) 64Cu alone (kBq) Dual-isotope phantoms[99mTc (kBq) + 64Cu (kBq)] 
18,500 37,000 18,500 + 37,000 
9,250 18,500 9,250 + 18,500 
5,550 11,100 5,550 + 11,100 
1,850 3,700 1,850 + 3,700 
925 1,850 925 + 1,850 
462.5 925 462.5 + 925 
231.3 462.5 231.3 + 462.5 
115.6 231.3 115.6 + 231.3 
0 0 0 + 0 
 
Table 2: Radioactivity concentration in the phantoms used in phantom study 2 
 Dual-isotope phantoms 
99mTc : 64Cu ratio 99mTc (kBq) 64Cu (kBq) 
1 : 1 1,850 1,850 
0.5 : 1 925 1,850 
0.25 : 1 462.5 1,850 
0.125 : 1 231.3 1,850 
0.0625 : 1 115.6 1,850 
0 : 1 0 1,850 
The incubated cells were trypsinized to detach them from the plates, and the number of cells was counted with a 
Cytorecon (GE Healthcare, Princeton, NJ). The BALB/c male nude mice (age: 6 weeks; body weight: 20-25 g) 
were purchased from Japan SLC (Shizuoka, Japan). The HT-29 cells suspended in phosphate-buffered saline (1 × 
107 cells) were subcutaneously injected into the femoral region of the right hind leg of the BALB/c nude mouse. 
When tumors reached approximately 8 to 12 mm in diameters, in which no obvious necrotic foci were observed, 
the imaging study was performed (n = 4). We intravenously injected 37 MBq of 64Cu-ATSM and 18.5 MBq of 
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99mTc-HSA into a mouse at 1 h and 10 min before the SPECT/PET scan, respectively. Injection dose and timing 
of these tracers were decided based on the previous studies [17, 38, 39].Each probe was dissolved in 100 μl of 
saline. A 20-min SPECT/PET scan, followed by CT scan, was performed, focusing on the tumor region. During 
the scans, the mice remained under 2% isoflurane anesthesia, and body temperature was maintained with a heater 
during the scans, on the attached measurement stage. With the reconstructed and registered images, the regions of 
interest (ROIs) were positioned on the tumor regions. The standardized uptake values (SUVs), the mean activity 
concentration divided by the injected activity per body weight, were calculated for each pixel in the ROIs. For the 
evaluation of acquired images, high-uptake regions for 99mTc and 64Cu were determined with various threshold 
values (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% of each SUVmaxvalue in each ROI) and the 
percentage of overlapped areas of 99mTc and 64Cu high-uptake regions in the ROIs were calculated: percentage of 
overlapped area = (areas of both 99mTc and 64Cu high uptake in the ROI) / (all areas of the ROI) × 100. From this, 
the minimal threshold value, which shows little overlap of 99mTc-HSA and 64Cu-ATSM high-uptake regions, was 
determined in the HT-29 tumor model. 
1.5. Ethics statement 
Animal experiments in this study were carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of our institution. The protocol was approved by the Animal Ethics 
Committee of our institution (Permit Number: M40-01). All efforts were made to minimize suffering in the 
animal experiments. 
2. Results 
2.1. Phantom studies 
In phantom study 1, the radioactivity of phantoms containing mixed dual isotopes (99mTc + 64Cu) and single 
isotopes (99mTc or 64Cu), was measured by SPECT/PET/CT imaging. Figure 1 shows the representative energy 
spectra of 99mTc alone (Figure 1a), 64Cu alone (Figure 1b), and dual isotopes (99mTc + 64Cu)(Figure 1c), 
respectively. We observed a single main peak of 99mTc (140 keV) in the spectrum of 99mTcalone, while the 
spectrum of 64Cu alone showed a primary photopeak (511 keV) and the broad peak, which is considered to be the 
backscatter of photons derived from 64Cu [17]. In the spectrum of 99mTc + 64Cu, the backscatter of photons 
derived from 64Cu overlapped with the main peak of 99mTc. Since there was no peak at 511 keV in the spectrum of 
99mTcalone, photons of 511 keV in dual isotopes (99mTc + 64Cu) were considered to be derived from 64Cu. Figure 
2a shows the comparison between the 99mTcradioactivity measured by SPECT/PET/CT images and that of 
standard radioactivity in phantoms with dual isotopes (99mTc + 64Cu) and single isotopes (99mTc alone) in the 
range of 0 to 18,500 kBq for 99mTc and 0 to 37,000 kBq for 64Cu. The 99mTcradioactivity obtained by 
SPECT/PET/CT imaging was proportional to standard radioactivity, and the slope was almost 1, which were 
similar in both dual- and single-isotope phantoms: slope = 0.96 and R2 = 0.99 for 99mTc in phantoms with dual 
isotopes (99mTc + 64Cu), and slope = 1.01 and R2 = 0.99 for 99mTc in phantoms with 99mTc alone, respectively. 
This result was similar in the case of 64Curadioactivity in the comparison between phantoms with dual-isotopes 
(99mTc + 64Cu) and single isotopes (64Cu alone): slope = 0.96 and R2 = 0.99 for 64Cu in phantoms with dual 
isotopes (99mTc + 64Cu), and slope = 1.05 and R2 = 0.99 for 64Cu in phantoms with 64Cu alone, respectively 
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(Figure 2b). These data mean that radioactivity obtained by SPECT/PET/CT imaging with this method is 
consistent with that of standards in the range of this experiment. 
 
Figure 1 :Representative energy spectra measured by the SPECT/PET/CT system 
The energy spectra for 99mTc alone (115.6 kBq) (a), 64Cu alone (231.3 kBq) (b), and dual isotopes (99mTc + 64Cu) 
(115.6 kBq for 99mTc, and 231.3 kBq for 64Cu) (c). There was a 140-keV primary photopeak in the spectrum of 
99mTcalone, a 511-keV primary photopeak (annihilation γ-photons), and a backscatter photopeak in the spectrum 
of 64Cu alone. 
(a)The99mTcradioactivity measured using SPECT/PET/CT (y axis) plotted against the standard radioactivity (x 
axis) in phantoms with single isotopes (99mTc alone) (red line) and dual isotopes (99mTc + 64Cu) (blue line) in 
various concentrations, at a radioactivity ratio of 99mTc :64Cu = 1 : 2 (see Table 1). (b) The 64Curadioactivity 
measured by SPECT/PET/CT (y axis) plotted against the standard radioactivity (x axis) in phantoms with single 
isotopes (64Cu alone) (green line) and dual isotopes (99mTc + 64Cu) (blue line) in various concentrations, with a 
radioactivity ratio of 99mTc :64Cu = 1 : 2 (see Table 1). 
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In phantom study 2, the 99mTc radioactivity of phantoms mixed with 99mTc at various ratios to a given amount of 
64Cu was measured with SPECT/PET/CT. In this experiment, we focused on the quantitativity at the low content 
of 99mTc to 64Cu, since the spectra data showed that the main peak of 99mTc overlapped with the backscatter 
photopeak of 64Cu. Figure 3 shows the comparison between 99mTc radioactivity measured by SPECT/PET/CT 
imaging and that of standard radioactivity (99mTc: 64Cu ratio = 0, 0.0625, 0.125, 0.25, 0.5, 1: 1; 64Cu radioactivity 
= 1850 kBq). The 99mTc radioactivity obtained by SPECT/PET/CT imaging was proportional to standard 
radioactivity and the slope was 0.99 (R2 = 0.99). The 99mTc radioactivity was consistent between SPECT/PET/CT 
imaging and standard radioactivity, even at the lowest 99mTc: 64Cu ratio (0.0625:1). 
 
Figure 2: Comparison between radioactivity measured by SPECT/PET/CT and that of standard radioactivity in 
phantom study 1 
2.2. In vivo99mTc/64Cu dual-isotope imaging study 
Thein vivo SPECT/PET/CT imaging study was performed with HT-29 tumor-bearing mice, injected with 64Cu-
ATSM (37 MBq) and 99mTc-HSA (18.5 MBq). Figure 4 shows representative images of 99mTc-HSA (Figure 4a) 
and 64Cu-ATSM (Figure 4b) by SPECT/PET/CT of a HT-29 tumor. The 99mTc-HSA uptake regions, colored 
red,and the 64Cu-ATSM uptake regions, colored green, were barely overlapped in the merged image (Figure 4c). 
Figure 5a and 5b indicate the percentage of high uptake regions, determined with various threshold values, within 
tumors for 99mTc and 64Cu, and Figure 5c shows the percentage of overlapped areas of high-uptake regions from 2 
tracers within the tumor, when various thresholds for both 99mTc and 64Cu in common were employed. The 
percentage of overlapped area was dramatically reduced, from 2.9% ± 0.9 at 30% threshold value to negligible 
(0.6% ± 0.3%) at 40% threshold value. This means 99mTc-HSA and 64Cu-ATSM high-uptake regions are little 
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overlapped when the threshold value was set to be 40% or higher of SUVmax, for both probes. Taken together, our 
data demonstrated that high-uptake regions of 99mTc-HSA and 64Cu-ATSM were clearly distinguished within 
tumors with this method using dual-isotope SPECT/PET/CT imaging. 
 
Figure 3: Comparison between radioactivity measured by SPECT/PET/CT and that of standard radioactivity in 
phantom study 2 
The 99mTc radioactivity measured by SPECT/PET/CT (y axis) plotted against the standard 99mTc radioactivity (x 
axis) in phantoms with 99mTc mixed at various ratios, to a given amount of 64Cu (see Table 2). 
 
Figure 4: In vivoSPECT/PET/CT imaging with 99mTc-HSA and 64Cu-ATSM 
Representative images of HT-29 tumor-bearing miceinjected with 18.5 MBq of 99mTc-HSA and 37 MBq of 64Cu-
ATSM are shown: 99mTc-HSA (a), 64Cu-ATSM (b), and merged 99mTc-HSA and 64Cu-ATSM (c). Dotted yellow 
circles indicate tumor regions in a through c. Red indicates 99mTc-HSA uptake in a and c, and green, 64Cu-ATSM 
uptake in b and c. 
The percentage of high-uptake regions of 99mTc-HSA (a) and 64Cu-ATSM (b) in tumors with various threshold 
values of %SUVmax for each probe are shown, as well as the percentage of overlapped areas between high-
uptake regions for 99mTc-HSA and 64Cu-ATSM in tumors, with various thresholds of %SUVmax for both probes 
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in common (c). Values are shown as mean ± SD (n = 4). 
 
Figure5: Analysis of the overlap between in vivo SPECT/PET/CT images of 99mTc-HSA and 64Cu-ATSM in 
HT-29 tumors 
3. Discussion 
Phantom study 1 demonstrated that 99mTc/64Cu SPECT/PET/CT showed high quantitativity, even when 2 isotopes 
co-existed, in the range of 0 to 18,500 kBq for 99mTc and 0 to 37,000 kBq for 64Cu, which seems to be wide 
enough to cover the range of radioactivity expected in in vivo experiments in mice. Phantom study 2 
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demonstrated that the quantitativity of 99mTc/64Cu SPECT/PET/CT remained high even when the content ratios of 
99mTc and 64Cu were changed. These experiments demonstrated that the cross-talk effect of the backscatter of 
photons derived from 64Cu overlapped with the main peak of 99mTc (140 keV) was minimal in this method, in the 
wide range of radioactivity and even at the low content of 99mTc to 64Cu. From our phantom studies, we 
confirmed that 99mTc/64Cu dual-isotope SPECT/PET/CT imaging would be feasible for in vivo experiments. 
Our in vivo study demonstrated that dual-isotope SPECT/PET/CT imaging can simultaneously visualize tumor 
vascularity detected by 99mTc-HSA and hypoxia detected by 64Cu-ATSM in a human colon carcinoma HT-
29tumor-bearing mouse model. Our data showed that overlapped areas between 99mTc-HSA and 64Cu-ATSM 
high-uptake regions, defined using the threshold value as 40% or higher of SUVmax within tumors, were very 
limited. Previously, many in vitro and in vivo studies have demonstrated that 64Cu-ATSM uptake is related to 
hypoxia within tumors [26-29]; it has been reported that 64Cu-ATSM high-uptake regions within tumors are 
hypovascular, undergoing cell cycle arrest but little necrosis, while 64Cu-ATSMlow-uptake regions are 
hypervascular, showing active cell proliferation [40, 41]. Also, previous preclinical and clinical studies have 
shown that 99mTc-HSA can detect tumor blood pool [19-21]. Considering this evidence, the observations in this 
study, which show little overlap between 99mTc-HSA and 64Cu-ATSM high-uptake regions, seem reasonable. The 
64Cu-ATSM autoradiography analyses in the previous preclinical studies have reported the distribution pattern of 
that the 64Cu-ATSM high-uptake regions associated with hypovascularity are located in the peripheral regions 
and the 64Cu-ATSM low-uptake regions associated with hypervascularity are located in the central regions within 
tumors, in several types of tumor-bearing mouse models including HT-29 [40, 42], which is a similar result to the 
present study with SPECT/PET/CT imaging. Since this probe has small molecular size and high membrane 
permeability [24] and the previous preclinical and clinical studies demonstrated that Cu-ATSM can reach to the 
central part in tumors [42, 43], the low of accumulation of 64Cu-ATSM in the central regions of HT-29 tumor 
model is considered not due to the low penetration. 
Our data demonstrated that dual-isotope SPECT/PET/CT with 99mTc-HSA and 64Cu-ATSM can simultaneously 
visualize vascularity and hypoxia within HT-29 tumors in mice. This methodology would have a potential to be 
applied to the other tumor-bearing mouse models. The method developed in this study enables coincident and 
precise observations of vascularity and hypoxia in vivo, which could help to understand the dynamics of tumor 
micro enviroments related to vascularity and hypoxia. In addition, this method could contribute to the 
development of new drugs and treatment strategies for antiangiogenic, antivascular, and antihypoxia therapy. 
4. Conclusion 
In conclusion, we developed a dual-isotope SPECT/PET/CT imaging with 99mTc-HSA and 64Cu-ATSM to 
simultaneously visualize vascularity and hypoxia with a HT-29 tumor-bearing mouse model. This could be useful 
for understanding tumor microenvironment and development. 
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